Delivery Order SPE2DB24D2205-SPE2DB25FEHPM
- Not listed
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed price delivery order valued at $25,624.50, with performance completion scheduled for September 15, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract and represents a competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for supply of XELJANZ XR 11 mg tablets in quantities of 30 units, with a contract ceiling value of $4,095.71. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through open competition. The order is scheduled for completion by September 10, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $13,322.71 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $15,662.64, represents a competitively awarded contract with no set-aside designation and is scheduled for completion by July 25, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $38,053.59 on September 11, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30s. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award under the company's existing contract vehicle with DLA. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This competitive, firm fixed-price delivery order carries a ceiling value of $28,456.06 and is scheduled for completion by June 3, 2025. The contract was awarded without any set-aside designation, reflecting open competition among qualified vendors. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $15,013.38 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30-count units. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The order is scheduled for completion by September 4, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of XELJANZ XR 11 mg tablets in a quantity of 30 units, valued at $29,798.59. This is a firm fixed-price delivery order issued without a set-aside designation, indicating it was competitively awarded. The contract is set to be completed by July 16, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $5,960.70 delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of XELJANZ XR 11 mg tablets (30-unit bottles). This firm fixed price delivery order, with an ultimate completion date of June 23, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHPMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of XELJANZ XR 11 mg tablets in a quantity of 30 units, valued at $8,055.93. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp regularly fulfills medical supply requirements across the Defense Health System through its comprehensive IDC vehicle. The XELJANZ XR tablets represent a specialty pharmaceutical product supporting military healthcare programs worldwide. AmerisourceBergen's demonstrated capability in meeting federal procurement requirements across multiple therapeutic domains, combined with its existing prime vendor status with DLA, positions the company to efficiently deliver pharmaceutical commodities to support defense medical operations and personnel healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/15/25 |